@article{fb890f2eb7494be99b6c294c7ac2ac9b,
title = "New hints towards a precision medicine strategy for IDH wild-type glioblastoma",
abstract = "Glioblastoma represents the most common primary malignancy of the central nervous system in adults and remains a largely incurable disease. The elucidation of disease subtypes based on mutational profiling, gene expression and DNA methylation has so far failed to translate into improved clinical outcomes. However, new knowledge emerging from the subtyping effort in the IDH-wild-type setting may provide directions for future precision therapies. Here, we review recent learnings in the field, and further consider how tumour microenvironment differences across subtypes may reveal novel contexts of vulnerability. We discuss recent treatment approaches and ongoing trials in the IDH-wild-type glioblastoma setting, and propose an integrated discovery stratagem incorporating multi-omics, single-cell technologies and computational approaches.",
keywords = "IDH-wt glioblastoma, multi-omics, precision therapy, tumour microenvironment",
author = "K. White and K. Connor and J. Clerkin and Murphy, {B. M.} and M. Salvucci and O'Farrell, {A. C.} and M. Rehm and D. O'Brien and Prehn, {J. H.M.} and Niclou, {S. P.} and Lamfers, {M. L.M.} and M. Verreault and A. Idbaih and R. Verhaak and A. Golebiewska and Byrne, {A. T.}",
note = "Funding Information: This work was supported by the European Union's Horizon 2020 research and innovation programme under the Marie Sk?odowska-Curie ?GLIOTRAIN? ITN initiative [grant number 766069] to ATB, KW, MR, BMM, JHMP, SPN, AI, MLML; the Beaumont Hospital Cancer Research and Development Trust to JC; Brain Tumor Ireland to JHMP; the program ?Investissements d'avenir? [grant number ANR-10-IAIHU-06], Institut Universitaire de Canc?rologie and INCA-DGOS-Inserm_12560 SiRIC CURAMUS funded by the French National Cancer Institute, the French Ministry of Solidarity and Health and Inserm to AI. AI reports grants and travel funding from Carthera, research grants from Transgene, Sanofi, Air Liquide and Nutritheragene travel funding from Leo Pharma, grants from outside the submitted work. All remaining authors have declared no conflicts of interest. Funding Information: AI reports grants and travel funding from Carthera, research grants from Transgene, Sanofi, Air Liquide and Nutritheragene travel funding from Leo Pharma, grants from outside the submitted work. All remaining authors have declared no conflicts of interest. Funding Information: This work was supported by the European Union's Horizon 2020 research and innovation programme under the Marie Sk{\l}odowska-Curie {\textquoteleft}GLIOTRAIN{\textquoteright} ITN initiative [grant number 766069 ] to ATB, KW, MR, BMM, JHMP, SPN, AI, MLML; the Beaumont Hospital Cancer Research and Development Trust to JC; Brain Tumor Ireland to JHMP; the program “ Investissements d'avenir ” [grant number ANR-10-IAIHU-06 ], Institut Universitaire de Canc{\'e}rologie and INCA-DGOS-Inserm_12560 SiRIC CURAMUS funded by the French National Cancer Institute , the French Ministry of Solidarity and Health and Inserm to AI. Publisher Copyright: {\textcopyright} 2020 The Authors",
year = "2020",
month = dec,
doi = "10.1016/j.annonc.2020.08.2336",
language = "English",
volume = "31",
pages = "1679--1692",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Elsevier Ltd.",
number = "12",
}